Patents by Inventor Guy Laidig

Guy Laidig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC GLUTAMINASE INHIBITORS
    Publication number: 20210292289
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: October 5, 2020
    Publication date: September 23, 2021
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
  • Heterocyclic glutaminase inhibitors
    Patent number: 10793535
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: October 6, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • Heterocyclic Inhibitors of Glutaminase
    Publication number: 20200165238
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: December 6, 2019
    Publication date: May 28, 2020
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric B. Sjogren
  • HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    Publication number: 20190315733
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: May 3, 2019
    Publication date: October 17, 2019
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
  • Heterocyclic inhibitors of glutaminase
    Patent number: 9938267
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 10, 2018
    Assignee: Calithera Biosciences, Inc.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
  • HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    Publication number: 20170369485
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: September 11, 2017
    Publication date: December 28, 2017
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS
    Publication number: 20150258082
    Abstract: The invention relates to methods of treating cancer, myeloproliferative disorders or immunological diseases with a combination of an immunomodulatory agent and a glutaminase inhibitor. The invention further relates to methods of treating cancer, myeloproliferative disorders, or immunological diseases that are resistant to one or more immunomodulatory agents.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 17, 2015
    Inventors: Francesco Parlati, Mirna L. Rodriguez, Matthew I. Gross, Terri L. Davis, Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
  • TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    Publication number: 20150004134
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: December 3, 2013
    Publication date: January 1, 2015
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    Publication number: 20140369961
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
  • Heterocyclic inhibitors of glutaminase
    Patent number: 8865718
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: October 21, 2014
    Assignee: Calithera Biosciences Inc.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • HETEROCYCLIC GLUTAMINASE INHIBITORS
    Publication number: 20140194421
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: November 15, 2013
    Publication date: July 10, 2014
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    Publication number: 20140050699
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 20, 2014
    Applicant: CALITHERA BIOSCIENCES INC.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • Heterocyclic inhibitors of glutaminase
    Patent number: 8604016
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: December 10, 2013
    Assignee: Calithera Biosciences Inc.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • Heterotricyclic compounds for use as HCV inhibitors
    Patent number: 7569580
    Abstract: The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a mammal.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: August 4, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sambaiah Thota, Rajinder Singh, Guy Laidig, Henry Lu
  • Compounds For Enzyme Inhibition
    Publication number: 20080090785
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: May 9, 2005
    Publication date: April 17, 2008
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, Kevin Shenk, Peggy Radel
  • Compounds for enzyme inhibition
    Publication number: 20070293465
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: June 19, 2007
    Publication date: December 20, 2007
    Applicant: Proteolix, Inc.
    Inventors: Kevin Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark Smyth, Mark Bennett, Guy Laidig
  • Compounds for enzyme inhibition
    Publication number: 20070191284
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: April 11, 2007
    Publication date: August 16, 2007
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser
  • Compounds for enzyme inhibition
    Publication number: 20070105786
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: November 9, 2006
    Publication date: May 10, 2007
    Applicant: Proteolix, Inc.
    Inventors: Han-Jie Zhou, Congcong Sun, Kevin Shenk, Guy Laidig
  • Compounds for enzyme inhibition
    Publication number: 20060088471
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus, such as a detectable label. Along with therapeutic utilities, these peptide based compounds can be used in assays useful for screening, monitoring, diagnostic and/or dosing purposes.
    Type: Application
    Filed: October 19, 2005
    Publication date: April 27, 2006
    Applicant: Proteolix, Inc.
    Inventors: Mark Bennett, Tonia Buchholz, Susan Demo, Guy Laidig, Evan Lewis, Mark Smyth
  • Compounds for enzyme inhibition
    Publication number: 20060030533
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: August 8, 2005
    Publication date: February 9, 2006
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig